Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKGH0R)

• Drug Name: GHRP-2 Drug Info
• Synonyms: Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy

Indication

Disease Entry	ICD 11	Status	REF
Growth hormone deficiency	5A61.3	Approved	[1]

• Cross-matching ID:
  PubChem CID: 6918245
  ChEBI ID: CHEBI:135890
  CAS Number: CAS 158861-67-7
  TTD Drug ID: DMKGH0R

Molecule-Related Drug Atlas

Drug(s) Targeting Growth hormone secretagogue receptor 1 (GHSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibutamoren	DMFJ8LT	Fibromyalgia	MG30.01	Approved	[4]
Macimorelin	DMQYJIR	Growth hormone deficiency	5A61.3	Approved	[5]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[6]
TZP-101	DMOE582	Gastrointestinal disease	DE2Z	Phase 2b	[7]
GTP-200	DM03NQS	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
RQ-00000005	DMBHN4K	Frailty	MG2A	Phase 2	[9]
Tabimorelin	DMNL9HO	Growth hormone deficiency	5A61.3	Phase 2	[10]
Ibutamoren mesylate	DMN2CM0	Growth hormone deficiency	5A61.3	Phase 2	[11]
Ipamorelin	DM9PJZT	Postoperative ileus	DA91-DB30	Phase 1/2	[12]
PF-05190457	DM7B2JC	Type-2 diabetes	5A11	Phase 1	[13]

Drug(s) Targeting Phosphogluconate dehydrogenase (PGD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrophosphate 2-	DMZQ75M	Discovery agent	N.A.	Investigative	[14]
5-deoxy-5-phosphono-D-arabinonate	DM65XZJ	Discovery agent	N.A.	Investigative	[15]
4-phospho-D-erythronate	DMW4KXQ	Discovery agent	N.A.	Investigative	[16]
6-Phosphogluconic Acid	DMB1QCY	Discovery agent	N.A.	Investigative	[17]
(2R)-2-Methyl-4,5-dideoxy	DM3K2TI	Discovery agent	N.A.	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth hormone secretagogue receptor 1 (GHSR)	TTWDC17	GHSR_HUMAN	Agonist	[2]
Phosphogluconate dehydrogenase (PGD)	TTZ3IFB	6PGD_HUMAN	Inhibitor	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
• [3] Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
• [4] Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
• [5] National Cancer Institute Drug Dictionary (drug id 735530).
• [6] Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
• [7] Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18.
• [8] Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
• [9] Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
• [10] Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
• [11] Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001 Jul;70(1):91-8.
• [12] Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.
• [13] A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014
• [14] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [15] Sugar derivatives as new 6-phosphogluconate dehydrogenase inhibitors selective for the parasite Trypanosoma brucei. Bioorg Med Chem. 2003 Apr 3;11(7):1207-14.
• [16] Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem. 2010 Jul 15;18(14):5056-62.
• [17] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.